TB-500
Synthesis and characterization of the N-terminal acetylated 17-23 fragment of thymosin beta 4 identified in TB-500, a product suspected to possess doping potential.
Evidence sourceOriginal analytical study · PMID 22962027
Studied inA TB-500 sample and synthesized peptide fragment analyzed in a laboratory
DesignChemical identity and detection-method study; no treatment population
Human protocolNot established from this laboratory or preclinical research
This source identifies material in a laboratory sample. It does not test a human regimen.
What researchers measured
- Identity of the acetylated thymosin beta 4 fragment in the analyzed sample
- Analytical detectability of the fragment in laboratory matrices
Laboratory identification methods
- Product identification
- High-resolution mass-spectrometry analysis of a TB-500 sample
- Reference fragment
- Solid-phase synthesis and analytical characterization of Ac-LKKTETQ
This source identified an acetylated fragment in a TB-500 sample. It does not show that every product labeled TB-500 has the same identity, nor does evidence on full-length thymosin beta 4 establish a TB-500 regimen.